INVO Fertility files 8-K with Q3 2025 results press release

Rhea-AI Filing Summary

INVO Fertility, Inc. filed a current report to announce that it has released a press release with its financial results for the quarter ended September 30, 2025. The company furnished this earnings press release as Exhibit 99.1 to the report, meaning it is provided for investors’ information but is not treated as part of the company’s formal, legally “filed” materials under securities laws unless later specifically incorporated by reference. INVO Fertility’s common stock continues to trade on The Nasdaq Stock Market under the symbol IVF.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001417926 0001417926 2025-11-17 2025-11-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) November 17, 2025

INVO FERTILITY, INC.

(Exact name of registrant as specified in its charter)

Nevada		001-39701		20-4036208
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

5582 Broadcast Court

Sarasota, FL 34240

(Address of principal executive offices, including zip code)

(978) 878-9505

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value		IVF		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On November 17, 2025, INVO Fertility, Inc. (the “Company”), issued a press release announcing financial results for the quarter ended September 30, 2025. The text of the press release is furnished as Exhibit 99.1 to this current report.

The information in this Item 2.02 and Exhibit 99.1 hereto shall not be deemed “filed” for the purposes of or otherwise subject to the liabilities under Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Unless expressly incorporated into a filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, the information contained in this Item 2.02 and Exhibit 99.1 hereto shall not be incorporated by reference into any Company filing, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release dated November 17, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document.)

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 17, 2025	INVO FERTILITY, INC.
	/s/ Steven Shum
	Steven Shum
	Chief Executive Officer

-3-

FAQ

What did INVO Fertility (IVF) disclose in this Form 8-K?

INVO Fertility disclosed that it issued a press release announcing its financial results for the quarter ended September 30, 2025, which is furnished as Exhibit 99.1.

Which period’s results does INVO Fertility (IVF) discuss in the new press release?

The press release furnished with this report covers INVO Fertility’s financial results for the quarter ended September 30, 2025.

How did INVO Fertility (IVF) treat the earnings press release under SEC rules?

The company stated that the information in Item 2.02 and Exhibit 99.1 is furnished, not filed, under the Securities Exchange Act of 1934, and is not incorporated into other filings unless expressly stated.

Where can investors find the detailed quarterly results for INVO Fertility (IVF)?

Investors can find the detailed quarterly results in Exhibit 99.1, which is the full press release referenced in this report.

What stock exchange lists INVO Fertility (IVF) common stock?

INVO Fertility’s common stock, with a par value of $0.0001 per share, is listed on The Nasdaq Stock Market under the trading symbol IVF.

Who signed the INVO Fertility (IVF) Form 8-K related to the quarterly results?

The report was signed on behalf of INVO Fertility by Steven Shum, the company’s Chief Executive Officer.